Jubilant Ingrevia Ltd. (JUBLINGREA) AI Stock Analysis

• Market Cap: ₹111.00B
• Dividend Yield: 0.72%
• Average Volume (3M): 23.13K
• Price to Earnings (P/E): 39.6
• Beta (1Y): 0.91
• Revenue Growth: 2.60%
• EPS Growth: 60.61%
• Country: IN
• Employees: 2,283
• Sector: Basic Materials
• Sector Strength: 60
• Industry: Biotechnology
• EPS (TTM): 4.80
• Shares Outstanding: 159,281,140
• 10 Day Avg. Volume: 23,238
• 30 Day Avg. Volume: 23,127
• PEG Ratio: 1.10
• Price to Book (P/B): 3.53
• Price to Sales (P/S): 2.47
• P/FCF Ratio: 72.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹785.00
• Price Target Upside: 12.65% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 58 Neutral
• Price Target: ₹785.00 ▲(12.65% Upside)

Jubilant Ingrevia Ltd. shows solid financial performance with stable profitability and a strong equity foundation. However, technical indicators suggest caution in the short term, and the high P/E ratio raises concerns about valuation. The lack of notable earnings call insights or corporate events leaves these areas unassessed.

Jubilant Ingrevia Ltd. Business Overview & Revenue Model

Company Description

Jubilant Ingrevia Ltd. is a global integrated life sciences company that operates in the specialty chemicals, nutrition, and health solutions sectors. The company is engaged in the production and distribution of a wide range of products including specialty chemicals, nutrition and health ingredients, and life science chemicals. These products serve a diverse set of industries such as pharmaceuticals, agrochemicals, consumer products, and industrial applications.

How the Company Makes Money

Jubilant Ingrevia makes money through a diversified revenue model primarily driven by the sale of its specialty chemicals, nutrition, and health solutions. The company's key revenue streams include the production and sale of specialty chemicals used in agrochemicals and consumer products, as well as life science chemicals that cater to the pharmaceutical and industrial sectors. Additionally, the company generates revenue from its nutrition and health solutions, which provide ingredients for food, feed, and personal care applications. Significant partnerships and a strong distribution network further bolster its earnings by expanding its market reach and enhancing operational efficiencies.

Jubilant Ingrevia Ltd. Financial Statement Overview

Summary

Jubilant Ingrevia Ltd. demonstrates strong financial health with consistent revenue and profit growth trends, stable margins, and a solid equity foundation. The company faces some challenges with revenue fluctuations and cash flow management, but its operational efficiency and profitability are strong overall.

Income Statement

The income statement shows a consistent growth trajectory in revenue over the years, with a noticeable increase in gross and net profit margins. However, there was a dip in revenue in 2024, followed by recovery in 2025. The EBIT and EBITDA margins have been stable, indicating efficient operations. Overall, the company demonstrates a strong ability to generate profits, though fluctuations in revenue growth present moderate risk.

Balance Sheet

The balance sheet reveals a solid equity position with a reasonable debt-to-equity ratio indicating moderate leverage. Return on equity has been healthy, supporting profitability. However, increasing total liabilities highlight potential risk if revenue does not continue to grow. The equity ratio is strong, suggesting good financial stability.

Cash Flow

The company's cash flow statement shows robust operating cash flow and a positive free cash flow trend in the latest year. The operating cash flow to net income ratio indicates strong cash generation relative to profits. However, previous periods showed negative free cash flow, pointing to potential challenges in managing capital expenditures effectively.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	41.25B	41.78B	41.00B	49.14B	47.40B	6.83B
Gross Profit	17.53B	16.07B	9.17B	19.56B	21.59B	2.78B
EBITDA	5.57B	5.57B	4.56B	8.63B	5.81B	1.07B
Net Income	2.51B	2.51B	1.83B	4.77B	3.08B	543.59M
Balance Sheet
Total Assets	50.32B	50.32B	47.32B	37.97B	42.59B	33.79B
Cash, Cash Equivalents and Short-Term Investments	1.15B	1.15B	787.84M	454.69M	1.08B	1.15B
Total Debt	7.64B	7.64B	7.40B	2.38B	4.07B	5.56B
Total Liabilities	21.05B	21.05B	19.94B	13.64B	15.93B	14.56B
Stockholders Equity	29.27B	29.27B	27.37B	24.33B	26.66B	19.23B
Cash Flow
Free Cash Flow	0.00	1.42B	-1.38B	2.23B	-189.30M	847.36M
Operating Cash Flow	0.00	5.08B	4.30B	4.53B	4.62B	1.12B
Investing Cash Flow	0.00	-3.93B	-5.70B	-718.56M	-4.72B	-436.55M
Financing Cash Flow	0.00	-1.29B	1.44B	-4.18B	416.00M	-723.65M

Jubilant Ingrevia Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 696.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JUBLINGREA, the sentiment is Negative. The current price of 696.85 is below the 20-day moving average (MA) of 772.57, below the 50-day MA of 759.32, and below the 200-day MA of 718.01, indicating a bearish trend. The MACD of -20.37 indicates Positive momentum. The RSI at 31.13 is Neutral, neither overbought nor oversold. The STOCH value of 6.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JUBLINGREA.

Jubilant Ingrevia Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMIORG	70 Neutral	₹106.79B	67.37		0.11%	40.11%	290.36%
ALKYLAMINE	69 Neutral	₹106.27B	57.09		0.48%	9.11%	24.90%
PRIVISCL	66 Neutral	₹94.99B	43.66		0.21%	21.50%	78.82%
ANURAS	64 Neutral	₹124.95B	133.72		0.07%	24.37%	29.89%
Sector *	61 Neutral	$10.08B	5.96	1.29%	3.00%	3.04%	-41.02%
JUBLINGREA	58 Neutral	₹111.00B	39.61		0.72%	2.60%	60.61%
SUDARSCHEM	52 Neutral	₹113.13B	63.99		0.32%	31.78%	-84.27%

Jubilant Ingrevia Ltd. Corporate Events

Jubilant Ingrevia Announces Virtual AGM and Annual Report Release

Jubilant Ingrevia Limited has announced that its 6th Annual General Meeting (AGM) will be held on August 29, 2025, via video conferencing. The company has published newspaper advertisements in Financial Express and Jansatta to inform shareholders about the AGM and the availability of the annual report for the financial year 2024-25, which will be sent electronically to registered shareholders.

Jubilant Ingrevia Engages with Global Investors at Nuvama India Conference

Jubilant Ingrevia Ltd. has announced its participation in the Nuvama India Conference in Singapore, where its management will engage with various institutional investors through one-on-one and group meetings. This initiative is part of the company’s strategy to strengthen relationships with key stakeholders and enhance its visibility in the investment community.

Jubilant Ingrevia Releases Q1 FY26 Investors’ Call Recording

Jubilant Ingrevia Limited has announced that the audio recording of its investors’ conference call, discussing the unaudited financial results for the quarter ending June 30, 2025, is now available on the company’s website. This disclosure aligns with the company’s commitment to transparency and regulatory compliance, potentially enhancing investor confidence and engagement.

Jubilant Ingrevia Releases Investor Call Recording for Q1 FY26

Jubilant Ingrevia Limited has announced that the audio recording of its investors’ conference call, discussing the unaudited financial results for the quarter ending June 30, 2025, is now available on the company’s website. This disclosure is in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, ensuring transparency and accessibility for stakeholders.

Jubilant Ingrevia Fulfills Rs. 100 Crore Commercial Paper Obligation

Jubilant Ingrevia Limited, a company involved in the chemical industry, has announced that it has successfully fulfilled its financial obligation by redeeming a Commercial Paper worth Rs. 100 Crores. This update signifies the company’s commitment to maintaining its financial health and reliability in the market, potentially strengthening its position and trust among stakeholders.